NewcelX Stock Moves Up Ahead of FDA Meeting on Diabetes Treatment
NewcelX Ltd. shares were slightly up in midday Nasdaq action Thursday, with traders watching the Swiss biotech ahead of its late-June meeting with U.S. regulators on its main cell therapy for type 1 diabetes. The shares traded at $3.18 by 11:47 a.m. EDT, up 2 cents, or 0.6% from the previous close. The session’s range so far has been $3.04 to $3.18. Volume was 13,288 shares at last check.